Green leaf pharmaceutical new drug Palione re-release mixed suspension muscle injection (LY03010) has been approved by the FDA

recently, GreenleafPharmaceuticals(the Group announced that its independently developednew drug(LY03010) for the treatment of schizophrenia and schizophrenic emotional disorders (LY03010) has been approved by the U.SFoodMedicines(
FDA() for clinical research in the United Statesabout LY03010LY03010 is given once a month by intramuscular injection to treat schizophrenia and schizophrenic emotional disordersAs a serious disease in psychotropic diseases, schizophrenia patients with low dependence lead to high recurrence rate, repeated disease, has become a major difficulty in the treatment of the diseasein clinical cases, non-compliance or partial compliance with treatment is one of the main factors of relapse and re-hospitalization, and the more relapses, the greater the deterioration of the disease, the longer the duration of the treatmentLY03010 can improve oral antipsychoticdrug(prevalent drug compliance in patients) Not only that, compared with another commercially available drug, LY03010 may make the patient's medication more convenient and further enhance the dependence on the drug by optimizing the initial administration central nervous system is one of the four core therapeutic areas of green leaf medicine for a long time Green leaf pharmaceutical in this field there are a number of new drugs in China and overseas markets are being developed simultaneously and has entered the clinical late stage, will soon be listed in major markets around the world include: the injection of lepeone reprieve microspheres (LY03004) for the treatment of schizophrenia and bipolar disorder( LY03004) has entered the final stage of NDA declaration preparation, will be declared in China and the United States, and injection of rothegotin reprieve microspheres (LY03003) for the treatment of Parkinson's disease And the treatment of depression Anshufasin reprieve tablets (LY03005) have entered the third phase of clinical in China and the United States, and the Mingdo-day patches the treatment of Alzheimer's disease are also in clinical trial (stage );